ClinicalTrials.gg
Active, not recruitingNCT07045337Updated Oct 23, 2026

Enhancing the Therapeutic Effect of Bracing for Adolescent Idiopathic Scoliosis With a Hybrid Bracing Protocol

An interventional study of Hybrid Bracing and Conventional fulltime Underarm Bracing in Adolescent Idiopathic Scoliosis (AIS), sponsored by Chinese University of Hong Kong. Active, not recruiting at 1 site in China. Open to female participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Jan 2022, registered Jun 2025).
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Scoliosis by Chinese University of Hong Kong — 2 open to participants now, 3 under way, none of them phase 3. Scoliosis · Chinese University of Hong Kong.

Planned enrollment
7th of 11
120 · median 149
Started
2022
with 1 other
No phase
9 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Scoliosis by Chinese University of Hong Kong, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 with no phase, and was the 13th registered.

Scoliosis

660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.

Browse Scoliosis studies →

Open to participants now

2 of the 14 studies in Scoliosis by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.

This study: 10 Years to 18 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Scoliosis by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

This is a prospective randomized controlled trial investigating the therapeutic effect of the Hybrid Bracing Protocol (HyBP) over the Conventional Brace in enhancing In-brace Correction (IBC) for adolescent idiopathic scoliosis(AIS).

Read the detailed description

Scoliosis is a complex three-dimensional spinal deformity and AIS is the commonest with a high prevalence of 2-4%. If left untreated, AIS can progress resulting in significant health problems including back degeneration and negative body images.

Bracing, such as Underarm Brace(UAB) used in our center, is indicated for skeletally immature patients with Cobb angle>20°. Another bracing system is a nighttime Lateral Bending Brace(LBB) designed in a bending position opposite to the convexity of the curve thus resulting in its overcorrection. If AIS becomes severe despite bracing, ultra-major surgery is indicated aiming at bony fusion of the deformed segment with instrumentation. It is therefore important to maximize treatment effectiveness with bracing to control curve progression and to avoid the need for surgery. In-brace Correction(IBC) is the percentage reduction in Cobb angle with bracing.

Studies have reported IBC is an important determinant of brace effectiveness. For enhancement of IBC, we put forward the Hybrid Bracing Protocol(HyBP) combining the use of daytime UAB and nighttime LBB. To be best of our knowledge, HyBP has never been reported in the literature. Our pilot study on 8 patients treated with HyBP and 8 Cobb-matched historical controls treated with fulltime UAB showed very promising results with IBC of 42.1±22.0% and 22.1±14.9% in the HyBP and control group respectively. We therefore propose a formal prospective rater-blinded randomized controlled trial on 120 skeletally immature AIS female subjects with single thoracolumbar or lumbar curve newly prescribed with bracing. They are randomly allocated to the HyBP Group or the Conventional Brace Group (CB Group). The primary objective is to determine if the HyBP Group has better treatment effect in terms of In-brace Correction (IBC) when compared with the CB group at 3-month and 18-month after bracing. This is a 3-year study proposal representing the first phase of a project, to be followed by the second phase of the project when all subjects of the entire cohort will be assessed on curve outcome at time of completion of bracing and at 2 years post-bracing. This study will carry significant clinical impacts in that, if proven useful, the HyBP can be used for enhancement of treatment outcomes with bracing, thus preventing the scoliotic spine from deterioration and to avoid the need for surgery.

03

Conditions studied

  • Adolescent Idiopathic Scoliosis (AIS)

Browse trials for

Keywords

  • Adolescent Idiopathic Scoliosis
  • Bracing
04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females with AIS diagnosed after detailed clinical and radiological evaluation by an experienced orthopaedic surgeon and
  2. having a single lumbar or thoracolumbar curve with Cobb angle between 20° - 40° and
  3. age 10 years and older when bracing is prescribed and
  4. Risser 0 to 2 and
  5. either pre-menarchal or less than 1 year post-menarchal and
  6. with no prior treatment for scoliosis

Exclusion criteria

Exclusion Criteria:

  1. presenting with associated musculoskeletal, neurological or other conditions possibly responsible for the curvature
  2. with previous surgical or orthotic treatment or
  3. physical or mental disability that prevent patients from complying with the bracing protocol
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Hybrid Bracing

    Hybrid Bracing Protocol (HyBP) combining the use of daytime Underarm Brace (UAB) and a nighttime Lateral Bending Brace

    Other: Hybrid Bracing

  • Active comparator
    Conventional fulltime underarm bracing (UAB)

    Conventional group uses fulltime underarm bracing (UAB)

    Other: Conventional fulltime Underarm Bracing

Interventions

  • OtherHybrid Bracing

    Hybrid Bracing includes daytime Underarm Brace(UAB) and nighttime Lateral Bending Brace(LBB)

  • OtherConventional fulltime Underarm Bracing

    Conventional group includes fulltime Underarm Brace (UAB) only.

06

What researchers measure

Primary outcomes

  1. In-brace Correction (IBC)

    Although bracing is considered to be useful, its effectiveness hinges on various factors one of which is the in-brace curve correction, ie In-brace Correction (IBC). IBC is defined as the percentage of Cobb angle change during an X-ray with the brace fitted on the patient.

    Time frame: From date of randomization, assessed up to 2 years after bracing stopped at skeletal maturity

Secondary outcomes

  1. Curve progression

    To determine if the HyBP has better treatment outcomes in terms of control of curve progression when compared with the conventional fulltime UAB

    Time frame: From date of randomization, assessed up to 2 years after bracing stopped at skeletal maturity

  2. Quality of life questionnaires

    To determine if the HyBP has better outcomes when compared with the conventional fulltime UAB in terms of quality of life as assessed by SRS-22r, Spinal Appearance Questionnaire and the Brace Questionnaire

    Time frame: From date of randomization, assessed up to 2 years after bracing stopped at skeletal maturity

07

Study locations

1 site
08

References and documents

Publications

  • Lau AYC, Kee HM, Yang KG, Kwan ECK, Hung ALH, Lee WYW, Wong MS, Cheng JCY, Lam TP. Full-time bracing versus hybrid bracing in adolescent idiopathic scoliosis: study protocol for a randomised controlled trial. Trials. 2026 May 19;27(1):483. doi: 10.1186/s13063-026-09787-0. PubMed 42152027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Patient privacy

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jul 2027, 66 months after the start.

Of 224 non-industry interventional studies with no phase under Scoliosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 58. This study's planned 66 months is above that.

Counting every sponsor, half of 234 studies reached it within 22 months; a quarter within 8 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Dec 2025 → Jul 2027 and completion Dec 2025 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jul 1, 2025
StartActual
Jan 1, 2022
Primary completionEst.
Jul 31, 2027was Dec 2025
CompletionEst.
Jul 31, 2027was Dec 2025
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Jul 31, 2027
Oct 23, 2026
Study completion
Dec 31, 2025→Jul 31, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Dec 31, 2025→Jul 31, 2027
    Study completion Dec 31, 2025→Jul 31, 2027
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07045337
Responsible party
Tsz-ping Lam (Clinical Professional Consultant, Chinese University of Hong Kong) — Principal investigator
First posted
Jul 1, 2025
Start date
Jan 1, 2022
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Adam Yiu Chung Lau, FRCSEd (Orth)
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion